Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. News
  3. metabolic acidosis
Show results for
Products
Applications
Companies
News
Downloads
Refine by
Date

Metabolic Acidosis Articles & Analysis

1 news found
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Grade 3 or higher events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, acute respiratory distress syndrome (ARDS), atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, multiple organ dysfunction syndrome and HLH/MAS. ...

ByBristol Myers Squibb Corporate

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you